This site is intended for health professionals only
Saturday 23 February 2019
Share |

Topic: Cardiovascular medicine

May 21, 2018
The study analysed data from more than 421,000 people aged 60–69 in both GP medical records and in the UK Biobank research study. Participants were followed up over ten years.

New research has shown that older people with very low heart disease risks also have very little frailty, raising the possibility that frailty could be prevented.

 

The largest study of its kind, led by the University of Exeter, found that even small reductions in risk factors helped to reduce frailty, as well as dementia, chronic pain, and other disabling conditions of old age.

 

May 17, 2018
New indication supports Amgen’s commitment to reduce the risk of recurrent cardiovascular events faced by heart attack and stroke survivors

Amgen has announced announced that the European Commission (EC) has approved a new indication in the Repatha® (evolocumab) label for adults with established atherosclerotic cardiovascular disease (myocardial infarction, stroke or peripheral arterial disease) to reduce cardiovascular risk by lowering low-density lipoprotein cholesterol (LDL-C) levels.

 

April 23, 2018
<p>Antibodies were found in plasma and heart muscle of end-stage heart failure patients</p>

Patients’ own immune response has the potential to prevent the development and progression of heart failure, according to research presented today at Frontiers in CardioVascular Biology (FCVB) 2018, a European Society of Cardiology congress.1

 

The study found antibodies in the plasma and heart muscle of end-stage heart failure patients.
 

April 23, 2018
<p>Older women in the study had mitochondrial dysfunction, reduced antioxidant proteins, and increased inflammation</p>

Researchers have discovered the molecular basis for the increased incidence of cardiovascular diseases in older women.

 

The study, which was presented at Frontiers in CardioVascular Biology (FCVB) 2018, a European Society of Cardiology (ESC) congress found that older women had mitochondrial dysfunction, reduced antioxidant proteins, and increased inflammation.1
 

March 19, 2018
Safe and effective use of NOACs for stroke prevention in patients with atrial fibrillation

A new version of the EHRA Practical Guide on the use of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation has been published online in the European Heart Journal and an executive summary in EP Europace,and presented at EHRA 2018.1–3

 

The guide, now in its third edition with more than 400,000 copies of previous versions distributed worldwide, was produced by the European Heart Rhythm Association (EHRA), a branch of the ESC.
 

March 19, 2018
International consensus document on arrhythmias and cognitive function has been published

Patients with atrial fibrillation could reduce the risk of dementia by taking stroke prevention medications, according to recommendations published online in EP Europace,1 a European Society of Cardiology journal, and presented at EHRA 2018.2

 

February 8, 2018
Heart disease patients should seek medical advice before adopting a very low calorie diet

Crash diets can cause a transient deterioration in heart function, according to research presented at CMR 2018.1 Patients with heart disease should seek medical advice before adopting a very low calorie diet.
 

Crash diets, also called meal replacement programmes, have become increasingly fashionable in the past few years,” said lead author Dr Jennifer Rayner, clinical research fellow, Oxford Centre for Magnetic Resonance, University of Oxford, Oxford, UK.
 

February 8, 2018
Doctors have developed a new five-minute procedure to scan the blood vessels which offers hope for claustrophobic patients unable to tolerate the conventional longer test

Magnetic resonance angiography (MRA) is a magnetic resonance imaging (MRI) exam that takes pictures of the blood vessels. Physicians use the images to diagnose diseases of the blood vessels, such as aneurysms or blockages.
 

May 5, 2017
Of patients surveyed who currently did not self-monitor, 86% said that they would consider doing so

A new patient survey carried out by the AF Association showed that the majority of patients surveyed, who are currently on a vitamin K antagonist such as warfarin, agreed that patient self-monitoring (PSM) would give 79% of them, who would prefer to live a life free from frequent clinic visits, the option to do so.

 

November 17, 2016
Nearly two-thirds of patients experienced plaque regression with Repatha (evolocumab) on top of optimised statin therapy

Amgen has announced that adding Repatha® (evolocumab) to optimised statin therapy resulted in statistically significant regression of atherosclerosis in patients with coronary artery disease (CAD).

 

The detailed results from the GLAGOV Phase III coronary intravascular ultrasound imaging trial were presented at a Late-Breaking Clinical Trials Session of the American Heart Association (AHA) Scientific Sessions 2016 and simultaneously published in the Journal of the American Medical Association.
 

September 8, 2016
A review of 135,000 patients with atrial fibrillation at more than a 1000 GP practices led to over 25,000 medical interventions, which is believed to have prevented hundreds of strokes and led to substantial cost savings

Atrial fibrillation (AF) is one of the most common forms of abnormal heart rhythm and a major cause of stroke. The abnormal rhythm prevents the heart from pumping effectively allowing blood to pool in the upper chambers called the atria. This pooling can result in the formation of a clot which can break loose and cause a stroke.

September 1, 2016
New analyses from the GARFIELD-AF registry show that a novel computer-generated machine learning risk model – the GARFIELD-AF Score – is substantially superior to CHA2DS2-VASc in predicting all-cause mortality, ischaemic stroke/systemic embolism and major bleeding in low-risk patients

New analyses from the Global Anticoagulant Registry in the FIELD – Atrial Fibrillation (GARFIELD-AF) show that a novel computer-generated machine learning risk model – the GARFIELD-AF Score – is superior to CHA2DS2-VASc in predicting all-cause mortality, ischaemic stroke/systemic embolism (SE) and major bleeding in low-risk patients.

A simplified GARFIELD-AF Score, potentially suitable for web applications, has been developed and its performance assessed using an independent contemporary registry from the USA, ORBIT-AF.

April 28, 2016
In guidance published this week NICE has recommended new heart failure drug sacubitril valsartan (Entresto, Novartis), the first drug of its kind, as an option for some people with heart failure

The guidance recommends the £3 per day treatment for this life-threatening condition in over 100,000 people with moderate to very severe symptoms whose heart is only able to pump a reduced amount of oxygenated blood around the body (known as a reduced ejection fraction), and whose heart failure is not controlled by the commonly used drugs, ACE inhibitors or ARBs.

 

April 15, 2016
Available in new presentation strength of 0.1mg/ml to maximise accuracy and flexibility of dosing

Martindale Pharma, the UK-based leading international specialty pharmaceutical company, announced the UK launch of Phenylephrine, a new strength of the selective vasopressor drug for the treatment of hypotension associated with anaesthesia. Phenylephrine will be available in a 10ml ampoule at a strength of 0.1mg/ml.
 

March 9, 2016
Sacubitril/valsartan represents a breakthrough therapeutic option for adult patients with symptomatic chronic heart failure with reduced ejection fraction

January 20, 2016
Novartis drug Entresto™ (sacubitril/valsartan) approved for use in adults with symptomatic chronic heart failure with reduced ejection fraction reduces mortality risk compared with current treatment according to study

Novartis announced Entresto™ (sacubitril/valsartan) for the treatment of adult patients with symptomatic chronic heart failure with reduced ejection fraction (HFrEF) is now available in the UK. Sacubitril/valsartan significantly reduces the risk of cardiovascular death and first hospitalisation for heart failure by 20% when compared to ACE-inhibitor, enalapril1 (absolute risk reduction: 4.7%).
 

 

September 25, 2015
Positive opinion from EU review body puts Entresto (sacubitril valsartan) on track to be approved for HFrEF patients across Europe by the end of 2015

Novartis announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Entresto™ (sacubitril valsartan). Pending final approval by the European Commission (EC), Entresto (sacubitril valsartan), previously known as LCZ696, will be licensed for use in the UK for the treatment of adult patients with symptomatic chronic heart failure and reduced ejection fraction (HFrEF).

 

September 3, 2015
Global atrial fibrillation registry presents two-year outcomes data in more than 17,000 newly diagnosed AF patients The unique breadth and maturity of GARFIELD-AF Registry data presented at ESC Congress 2015 provides real-world insights on the evolution of managing AF in everyday clinical practice across the globe

The first-ever two-year outcomes from the Global Anticoagulant Registry in the Field – Atrial Fibrillation (GARFIELD-AF) showcased at ESC Congress 2015 expose that all-cause death was the most frequent major event in more than 17,000 newly diagnosed AF patients, far exceeding the rate of stroke or major bleeding. These two-year prospective outcomes from cohorts 1 and 2 show a mortality rate of 3.83% per person year compared to stroke rates of 1.25% per person year and major bleeding rates of 0.70% per person year. (1)       

September 3, 2015
Novartis will provide LCZ696 (sacubitril valsartan) to the NHS for eligible patients enrolled in EAMS

Novartis announced that its investigational heart failure treatment LCZ696 (sacubitril valsartan) has been given a positive scientific opinion under the Medicines and Healthcare products Regulatory Agency (MHRA) Early Access to Medicines Scheme (EAMS) for patients with significant unmet medical need.  This allows LCZ696 (sacubitril valsartan) to be made available to eligible patients before a final European licensing decision is made.
 

 

May 28, 2015
Acute heart failure is a common reason for admission to hospital and is a medical emergency. This article focuses on the treatment options for the management of this patient group

 

May 28, 2015
Ibuprofen is an effective therapy for closing a haemodynamically significant patent ductus arteriosus and has been shown to be safer and better tolerated than indometacin

 

May 28, 2015
Latest data from multicentre trials support the thesis that using lower iodine concentration achieves adequate results in terms of image quality in coronary computed tomography investigations

 

April 27, 2015
The European Committee for Medicinal Products for Human Use recommended approval of once-daily Lixiana®. The positive opinion is based on data from the ENGAGE AF-TIMI 48 and Hokusai-VTE studies, the largest single comparative global trials of a novel oral anticoagulant in patients with non-valvular atrial fibrillation or venous thromboembolism, involving 21,105 and 8,292 patients, respectively. Daiichi Sankyo looks forward to receiving approval decision by the European Commission soon, which is the basis for marketing authorisation in all European Union member states.
  • The European Committee for Medicinal Products for Human Use recommended approval of once-daily Lixiana®.
  •  The positive opinion is based on data from the ENGAGE AF-TIMI 48 and Hokusai-VTE studies, the largest single comparative global trials of a novel oral anticoagulant in patients with non-valvular atrial fibrillation or venous thromboembolism, involving 21,105 and 8,292 patients, respectively. 
April 23, 2015
Novartis is delighted to announce that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted a Promising Innovative Medicine (PIM) designation for its investigational medicine for patients with heart failure (HF) with reduced ejection fraction, LCZ696 (sacubitril/valsartan).

Novartis is delighted to announce that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted a Promising Innovative Medicine (PIM) designation for its investigational medicine for patients with heart failure (HF) with reduced ejection fraction, LCZ696 (sacubitril/valsartan).

You are leaving www.nursinginpractice.com

You are currently leaving the Nursing in Practice site. Are you sure you want to proceed?

Close

Respect for nurses: Sign up to our e-petition TODAY

The Nursing in Practice Respect campaign is now live! Over the coming months, we're set to highlight the vital contribution and efforts of primary care and community care nurses throughout the UK.

As part of our campaign, Nursing in Practice is looking to call on parliament to set up a debate to celebrate the vital work that you do.


GET INVOLVED: SIGN OUR E-PETITION

Close

Calling all primary care nurses! 'Like' our Nursing in Practice Facebook page to enter our free draw to win a £25 M&S voucher




http://www.facebook.com/NursinginPracticeMagazine